Bruce Eaton - Jul 23, 2021 Form 3 Insider Report for Editas Medicine, Inc. (EDIT)

Signature
/s/ Bruce Eaton
Stock symbol
EDIT
Transactions as of
Jul 23, 2021
Transactions value $
$0
Form type
3
Date filed
7/30/2021, 04:11 PM
Next filing
Apr 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding EDIT Common Stock 28.3K Jul 23, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding EDIT Stock Option (right to buy) Jul 23, 2021 Common Stock 110K $33.98 Direct F2
holding EDIT Stock Option (right to buy) Jul 23, 2021 Common Stock 48.8K $21.10 Direct F3
holding EDIT Stock Option (right to buy) Jul 23, 2021 Common Stock 45K $28.05 Direct F4
holding EDIT Stock Option (right to buy) Jul 23, 2021 Common Stock 17.1K $45.69 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects (i) 9,830 shares of common stock and (ii) 18,483 shares of common stock received by the Reporting Person in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, of which (A) 3,555 shares are scheduled to vest over four years with 25% of the units having vested on February 6, 2020 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through February 6, 2023, (B) 5,157 shares are scheduled to vest over four years with 25% of the units having vested on February 6, 2021 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through February 6, 2024, (C) 4,289 shares are scheduled to vest in full on March 31, 2022, and (D) 5,482 shares are scheduled to vest over four years with 25% of the units vesting on March 2, 2022 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2025.
F2 This option was granted on February 5, 2018 and is scheduled to vest over four years, with 25% of the shares having vested on January 22, 2019 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through January 22, 2022.
F3 This option was granted on February 6, 2019 and is scheduled to vest over four years in equal monthly installments beginning on March 6, 2019 through February 6, 2023.
F4 This option was granted on February 6, 2020 and is scheduled to vest over four years in equal monthly installments beginning on March 6, 2020 through February 6, 2024.
F5 This option was granted on March 2, 2021 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2021 through March 2, 2025.